News

Nanomerics' Oral Amphotericin B Promises Better Treatment for Millions

www.who.int/entity/leishmaniasis/Leish_viscerial.jpgNanomerics has developed a nano-enabled orally active form of Amphotericin B which could provide improved access to efficacious therapy to millions of people affected by Leishmaniasis.

Nanomerics Announces Completion of Major Preclinical Toxicology Programme on its Molecular Envelope Technology

Nanomerics today announced the successful completion of a major preclinical toxicology programme on its Molecular Envelope Technology (MET), paving the way for the technology’s clinical testing.  Safety pharmacology, mutagenicity and a range of 28 day repeat dose Good Laboratory Practice (GLP) standard toxicology tests have been completed on two species (rodent and non-rodent).

Nanomerics CEO Andreas Schatzlein presents at OBN Investor Forum

OBN logoAt the upcoming 4th OBN Investor & CEO networking forum Nanomerics CEO Prof A Schatzlein will be presenting an update on the development of Nanomerics' lead products NM0127, a nasal analgesic peptide to replace opioid pain therapies, and NM0131, a once daily non-oily nano-enabled form of cyclosporin A for the treatment of dry eye syndrome.  

Fighting Fit - Nanomerics featured in CBI Business Voice Publication

moleculesIn the October edition of the CBI's  online publication 'Business Voice' journalist Dan Jellinek looks at how leading UK innovators contribute to the expanding UK life science sector. Nanomerics' CEO Prof Andreas Schatzlein describes how support from the EPSRC,  the Wellcome Trust, and Innovate UK has helped Nanomerics to translate scientific research into medicines which bring important patient benefits.

Prof Martin Koltzenburg Joins Nanomerics Advisory Board

Nanomerics is pleased to announce the strengthening of its Scientific Advisory Board with the appointment of Professor Martin Koltzenburg.  Professor Koltzenburg’s appointment will  support the clinical development of iNanomerics' lead product NM0127, a novel pain therapeutic based on an endogenous peptide.  


www.uclh.nhs.uk/OurServices/Consultants/PublishingImages/KoltzenburgMartin.jpg

Antibodies to the Brain - A High Impact Collaboration

Nanomerics is embarking on a new EPSRC funded collaborative research project with the Danish pharmaceutical company H Lundbeck, UCL, and Exeter University.  

LogosAs part of the new collaboration, the company aims to develop new and exciting ways to deliver antibodies to the brain, building on the molecular envelope technology Nanomerics has developed to deliver previously undeliverable drugs to the organ.
 

UCL’s School of Life and Medical Sciences Celebrates Enterprise Successes

UCL Enterprise publicationSpin-out Nanomerics and its founders were highlighted in UCL’s School of Life and Medical Sciences recently launched  'Enterprise' publication. The brochure, available here, celebrates recent success stories of translation of scientific knowledge. 

Nanomerics to Present at BIO Spring 2014

Nanomerics is pleased to announce that Nanomerics Chief Scientific Officer - Professor Ijeoma F.

Meet Nanomerics at BioSpring

BES logo
 
 
Nanomerics' CSO - Professor Ijeoma Uchegbu, will be attending BIO Spring (10th - 12th March 2014).  Plan to meet Nanomerics at BIO Spring.

Dr Alan Bye joins Nanomerics' Board of Directors.

logoNanomerics is pleased to announce the appointment of Dr Alan Bye to Nanomerics' Board of Directors.  Alan Bye is an experienced and accomplished pharmaceutical scientist who previously ran GSK's Centre of Excellence in Neuroscience.  Dr Bye has taken numerous products from concept to market and brings valuable industrial and product development experience to the board.

Pages